Quarterly report pursuant to Section 13 or 15(d)

Share Holders Equity (Deficit) (Details)

v3.19.3
Share Holders Equity (Deficit) (Details) - Warrants
9 Months Ended
Sep. 30, 2019
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Number of warrants, beginning balance (in shares) 17,818,844
Number of warrants granted, series B preferred stock (in shares) 9,262,500
Number of warrants granted, marathon debt (in shares) 1,840,275
Number of warrants exercised (in shares) 0
Number of warrants, ending balance (in shares) 28,921,619
Weighted average exercise price per warrant, beginning balance (in usd per share) | $ / shares $ 1.84
Weighted average exercise price per warrant granted, series B preferred stock (in usd per share) | $ / shares 1.62
Weighted average exercise price per warrant granted, marathon debt (in usd per share) | $ / shares 1.40
Weighted average exercise price per warrant, ending balance (in usd per share) | $ / shares $ 1.74
Weighted average remaining exercise term beginning balance 52 months
Weighted average remaining exercise term granted, series B preferred stock 48 months
Weighted average remaining exercise term granted, marathon debt 60 months
Weighted average remaining exercise term ending balance 49 months